Agile Therapeutics Inc. Stock
Price
Target price
-
-
-
-
-
?11.19
WKN: A3D7A3 / Symbol: AGRX / Name: Agile Therapeutics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Agile Therapeutics Inc. Stock
Based on 2 Buy predictions and 1 Sell predictions the sentiment towards Agile Therapeutics Inc. is rather balanced.
With a target price of 11 € there is potential for a 5198.65% increase which would mean more than doubling the current price of 0.21 € for Agile Therapeutics Inc..
Our community identified positive and negative aspects for Agile Therapeutics Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Agile Therapeutics Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Agile Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agile Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agile Therapeutics Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 3.600% | -1.640% | -12.849% | 41.749% | 3.737% | -16.140% | - |
| Salarius Pharmaceuticals Inc. | 1.400% | 3.333% | 6.373% | -63.833% | -21.802% | -98.281% | -99.993% |
| Brainstorm Cell | -5.760% | -2.456% | -18.607% | -82.011% | 114.009% | -83.339% | - |
Comments
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Show more
Ratings data for AGRX provided by MarketBeat